Frank J. Lowery

Frank J. Lowery

Auto-generated profile, based on publicly available information

Frank J. Lowery

Surgery Branch, NCI, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2015 in Nature
Verified
Journal Article
Closed access
PDF file
LZLin Zhang
Lin Zhang
SZSiyuan Zhang
Siyuan Zhang
JYJun Yao
Jun Yao
FLFrank J. Lowery
Frank J. Lowery
QZQingling Zhang
Qingling Zhang
DYDihua Yu
Dihua Yu

11 December 2020 in Science
Verified
Journal Article
Closed access
PDF file
SKSri Krishna
Sri Krishna
FLFrank J. Lowery
Frank J. Lowery
ACAmy R. Copeland
Amy R. Copeland
EBErol Bahadiroglu
Erol Bahadiroglu
RMRatnadeep Mukherjee
Ratnadeep Mukherjee
SRSteven A. Rosenberg
Steven A. Rosenberg
Stem-like T cells mediate response: Adoptive cell transfer (ACT) is a type of immunotherapy that uses a patient's own T lymphocytes to recognize and attack cancer. ACT has been effective in treating certain patients with metastatic melanoma and is being applied to treat some epithelial cancers. Krishna et al. investigated why some cancer patients respond to ACT, whereas others do not. They identified a population of CD8 + T cells that had stem-like surface markers that were associated with effective tumor cell killing and favorable response of melanoma patients to ACT. Only a small subset of T cells specific against tumor mutations were found in this stem-like state, whereas most mutation-reactive T cells were terminally differentiated. These findings could be of value in improving cancer immunotherapy outcomes. Science , this issue p. 1328

3 February 2022 in Science
Verified
Journal Article
Closed access
FLFrank J. Lowery
Frank J. Lowery
SKSri Krishna
Sri Krishna
RYRami Yossef
Rami Yossef
NPNeilesh B. Parikh
Neilesh B. Parikh
PCPraveen D. Chatani
Praveen D. Chatani
SRSteven A. Rosenberg
Steven A. Rosenberg
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures of CD8 + and CD4 + neoantigen-reactive tumor-infiltrating lymphocytes (TILs). Neoantigen-specific TILs exhibited tumor-specific expansion with dysfunctional phenotypes, distinct from blood-emigrant bystanders and regulatory TILs. Prospective prediction and testing of 73 NeoTCR signature–derived clonotypes demonstrated that half of the tested TCRs recognized tumor antigens or autologous tumors. NeoTCR signatures identified TCRs that target driver neoantigens and nonmutated viral or tumor-associated antigens, suggesting a common metastatic TIL exhaustion program. NeoTCR signatures delineate the landscape of TILs across metastatic tumors, enabling successful TCR prediction based purely on TIL transcriptomic states for use in cancer immunotherapy.

23 June 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
SKSanghyun P. Kim
Sanghyun P. Kim
NVNolan R. Vale
Nolan R. Vale
NZNikolaos Zacharakis
Nikolaos Zacharakis
SKSri Krishna
Sri Krishna
ZYZhiya Yu
Zhiya Yu
SRSteven A. Rosenberg
Steven A. Rosenberg
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT targeting neoantigens, we focused on TP53 mutations commonly shared across different cancer types. We performed whole-exome sequencing on 163 patients with metastatic solid cancers, identified 78 who had TP53 missense mutations, and through immunologic screening, identified 21 unique T-cell reactivities. Here, we report a library of 39 T-cell receptors (TCR) targeting TP53 mutations shared among 7.3% of patients with solid tumors. These TCRs recognized tumor cells in a TP53 mutation- and human leucocyte antigen (HLA)-specific manner in vitro and in vivo. Twelve patients with chemorefractory epithelial cancers were treated with ex vivo–expanded autologous tumor-infiltrating lymphocytes (TIL) that were naturally reactive against TP53 mutations. However, limited clinical responses (2 partial responses among 12 patients) were seen. These infusions contained low frequencies of mutant p53–reactive TILs that had exhausted phenotypes and showed poor persistence. We also treated one patient who had chemorefractory breast cancer with ACT comprising autologous peripheral blood lymphocytes transduced with an allogeneic HLA-A*02–restricted TCR specific for p53R175H. The infused cells exhibited an improved immunophenotype and prolonged persistence compared with TIL ACT and the patient experienced an objective tumor regression (-55%) that lasted 6 months. Collectively, these proof-of-concept data suggest that the library of TCRs targeting shared p53 neoantigens should be further evaluated for the treatment of patients with advanced human cancers. See related Spotlight by Klebanoff, p. 919

1 February 2015 in Cancer Cell
Verified
Journal Article
Closed access
JXJia Xu
Jia Xu
SASunil Acharya
Sunil Acharya
Ozgur SahinOzgur Sahin
Ozgur Sahin
QZQingling Zhang
Qingling Zhang
YSYohei Saito
Yohei Saito
DYDihua Yu
Dihua Yu

15 September 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SZSiyuan Zhang
Siyuan Zhang
WHWen-Chien Huang
Wen-Chien Huang
LZLin Zhang
Lin Zhang
CZChenyu Zhang
Chenyu Zhang
FLFrank J. Lowery
Frank J. Lowery
DYDihua Yu
Dihua Yu
Despite better control of early-stage disease and improved overall survival of patients with breast cancer, the incidence of life-threatening brain metastases continues to increase in some of these patients. Unfortunately, other than palliative treatments there is no effective therapy for this condition. In this study, we reveal a critical role for Src activation in promoting brain metastasis in a preclinical model of breast cancer and we show how Src-targeting combinatorial regimens can treat HER2+ brain metastases in this model. We found that Src was hyperactivated in brain-seeking breast cancer cells derived from human cell lines or from patients' brain metastases. Mechanistically, Src activation promoted tumor cell extravasation into the brain parenchyma via permeabilization of the blood–brain barrier. When combined with the EGFR/HER2 dual-targeting drug lapatinib, an Src-targeting combinatorial regimen prevented outgrowth of disseminated breast cancer cells through the induction of cell-cycle arrest. More importantly, this combinatorial regimen inhibited the outgrowth of established experimental brain metastases, prolonging the survival of metastases-bearing mice. Our results provide a rationale for clinical evaluation of Src-targeting regimens to treat patients with breast cancer suffering from brain metastasis. Cancer Res; 73(18); 5764–74. ©2013 AACR.